Чтение онлайн

ЖАНРЫ

Используйте голову, чтобы спасти мозг. Профилактика деменции в любом возрасте
Шрифт:

Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1299–1306. doi: 10.1136/jnnp-2015-310548. Epub 2015 Aug 20.

Yassine HN, Braskie MN, Mack WJ, et al. Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ?4 carriers: a review. JAMA Neurol. 2017;74(3):339–347. doi: 10.1001/jamaneurol.2016.4899

Zhao C, Tsapanou A, Manly J, Schupf, N, Brickman AM, Gu, Y. Vitamin D intake is associated with dementia risk in the Washington Heights – Inwood Columbia Aging Project (WHICAP). Alzheimers Dement. 2020;16:1393–1401. doi: 10.1002/alz.12096

Chapter 8. Alcohol, Drugs, and Medications

Alexander CM, Seifert HA, Blouin RT, Conrad PF, Gross JB. Diphenhydramine enhances the interaction of hypercapnic and hypoxic ventilatory drive. Anesthesiology. 1994;80:789–795.

Boeuf-Cazou O, Bongue B, Ansiau D, Marquie J-C, Lapeyre-Mestre M. Impact of long-term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort. Eur J Clin Pharmacol. 2011;67:1045. doi: 10.1007/s00228-011-1047-y

Campbell NL, Holden R, Boustani MA. Preventing Alzheimer disease by deprescribing anticholinergic medications. JAMA Intern Med. 2019;179(8):1093–1094. doi: 10.1001/jamainternmed.2019.0676

Cohen PA, Avula B, Wang YH, Zakharevich I, Khan I. Five unapproved drugs found in cognitive enhancement supplements. Neurol Clin Pract. 2021;11(3):e303–e307. doi: 10.1212/CPJ.0000000000000960

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control For Further Reading 245 study. JAMA Intern Med. 2019;179(8):1084–1093. doi: 10.1001/jamaintern

Crowe S, Stranks E. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2018;33:901–911. doi: 10.1093/arclin/acx120

D’Amico G, deFranchis R, Dell’Era A, eds. National history and stages of cirrhosis and variceal hemorrhage. Springer Science+Business Media; 2014. doi: 10.1007/978-1-4939-0002-2_2

Esser MB, Sherk A, Liu Y, et al. Deaths and years of potential life lost from excessive alcohol use – United States, 2011–2015. Morbidity and Mortality Weekly Report. 2020;69:981–987. doi: 10.15585/mmwr.mm6930a1

Flippo TS, Holder WD. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg. 1993;128(12):1391–1395. doi: 10.1001/archsurg.1993.01420240099018

Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. doi: 10.1001/jamainternmed.2014.7663

Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry. 1986;49:341–345.

He Q, Chen X, Wu T, Li L, Fei X. Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies. J Clin Neurol. 2019;15(1):9–19. doi: 10.3988/jcn.2019.15.1.9. Epub 2018 Oct 26.

Islam MM, Iqbal U, Walther B, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology. 2016;47:181–191. doi: 10.1159/000454881

Kim JW, Lee DY, Lee BC, et al. Alcohol and cognition in the elderly: a review. Psychiatry Investig. 2012;9:8–16. doi: 10.4306/pi.2012.9.1.8

Kivimaki M, Singh-Manoux A, Batty GD, et al. Association of alcohol-induced loss of consciousness and overall alcohol consumption with risk for dementia. JAMA Netw Open. 2020;3(9):e2016084. doi: 10.1001/jamanetworkopen.2020.16084

National Institute on Alcohol Abuse and Alcoholism. Alcohol facts and statistics. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics

Oscar-Berman M, Marinkovic K. Alcoholism and the brain: an overview. Alcohol Res Health. 2003;27(2):125–133.

Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J Clin Psychopharmacol. 2002;22(3):285–293.

Raphael KC, Matuja SS, Shen NT, Liwa AC, Jaka H. Hepatic encephalopathy; prevalence, precipitating factors and challenges of management in a resource-limited setting. J Gastrointest Digest Syst. 2016;6(3):441. doi: 10.4172/2161-069X.1000441

Rosner S, Soyka M, Hajak G, Wehrle R, Englbrecht C. Eszopiclone for insomnia. Cochrane Database System Rev. 2013;8(CD010703). doi: 10.1002/14651858.CD010703

Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–513. doi: 10.1001/archinternmed.2007.106

Sabia S, Elbaz A, Britton A, Bell S, Dugravot A, Shipley M, Kivimaki M, Singh-Manoux A. Alcohol consumption and cognitive decline in early old age. Neurology. 2014;82(4):332–339. doi: 10.1212/WNL.0000000000000063. Epub 2014 Jan 15.

Sacks O, Shulman M. Steroid dementia: An overlooked diagnosis? Neurology. 2005;64:707–709.

Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J; QalyDays Study Group. Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study. Lancet Public Health. 2018;3(3):e124–132. doi: 10.1016/S2468-2667(18)30022-7. Epub 2018 Feb 21.

Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017;357:j2353. doi: 10.1136/bmj.j2353

Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735. doi: 10.1002/hep.27210. Epub 2014 Jul 8.

Weigand AJ, Bondi MW, Thomas KR, et al. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020;95(16) e2295–e2304. doi: 10.1212/WNL.0000000000010643

Поделиться с друзьями: